1. Home
  2. Directory
  3. Illinois
  4. Wheaton
  5. Ophthalmology
  6. NPI Profile
  7. Prescriptions 1720077530

DR. MICHELLE G SIMS MD
Prescription History 1720077530
Ophthalmology in Wheaton, IL


Quality Rating: 94.1 out of 100 score

NPI Status: Active since October 14, 2005

Contact Information

2015 N MAIN ST
WHEATON, IL
ZIP 60187
Phone: (630) 668-8250
Fax: (630) 668-8916

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MICHELLE G SIMS MD, an active Ophthalmology specialist practicing in Wheaton, IL. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 805 documented patient claims. Among these therapy options, the most frequently utilized medication is Prednisolone Acetate, which accounts for 346 claims alone.

Medication Index

Cyclosporine

Generic Formulation: CyclosporineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 780
IL State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply912
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 44.4% more claims than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,808.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$492.63

State Avg Cost Per Claim

$790.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Erythromycin

Generic Formulation: Erythromycin BaseSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 272
IL State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills46.9
Peer Average Days Supply567
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $405.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.93

State Avg Cost Per Claim

$16.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 22
30-Day Fills 53.9
Days Supply 1,605
IL State Average Benchmarks
Peer Average Claims141.0
Peer Average 30-Day Fills260.8
Peer Average Days Supply7,448
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 84.4% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $775.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$35.23

State Avg Cost Per Claim

$23.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Moxifloxacin

Generic Formulation: Moxifloxacin HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 283
30-Day Fills 283.0
Days Supply 3,991
IL State Average Benchmarks
Peer Average Claims92.0
Peer Average 30-Day Fills94.7
Peer Average Days Supply1,589
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 207.6% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,851.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.81

State Avg Cost Per Claim

$34.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.

Therapeutic Applications

This medication is a quinolone antibiotic used for eye infections.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 483
IL State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills37.5
Peer Average Days Supply543
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $543.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.46

State Avg Cost Per Claim

$14.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 346
30-Day Fills 374.4
Days Supply 9,059
IL State Average Benchmarks
Peer Average Claims111.0
Peer Average 30-Day Fills142.9
Peer Average Days Supply3,658
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 211.7% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,806.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.23

State Avg Cost Per Claim

$46.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Restasis

Generic Formulation: CyclosporineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 61
30-Day Fills 95.0
Days Supply 2,805
IL State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills60.9
Peer Average Days Supply1,791
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 64.9% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $62,902.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,031.20

State Avg Cost Per Claim

$1,071.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MICHELLE G SIMS MD provides transparency into local medical care patterns within Wheaton, IL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.